TherapeuticsMD (TXMD) Reports In-Line Q4 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results
February 21, 2019 4:05 PM EST
Successful Launch of IMVEXXY®, Strong Positive
Trends
Continue for Prescriptions and Patient Refills
BIJUVA Commercial Launch on Track for the Second Quarter of 2019
ANNOVERA Commercial Launch planned as Early as the Third Quarter of 2019
Conference Call Scheduled for 4:30 p.m. ET Today
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading womens healthcare company, today announced its commercial and corporate update for the fourth quarter and full-year ended December 31, 2018.
In 2018, we completed our most successful... More
